164 related articles for article (PubMed ID: 27859368)
1. Cancer predisposition syndromes: lessons for truly precision medicine.
Glaire MA; Brown M; Church DN; Tomlinson I
J Pathol; 2017 Jan; 241(2):226-235. PubMed ID: 27859368
[TBL] [Abstract][Full Text] [Related]
2. The emerging significance of secondary germline testing in cancer genomics.
Mandelker D; Zhang L
J Pathol; 2018 Apr; 244(5):610-615. PubMed ID: 29293272
[TBL] [Abstract][Full Text] [Related]
3. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
4. Monoallelic deleterious MUTYH germline variants as a driver for tumorigenesis.
Barreiro RAS; Sabbaga J; Rossi BM; Achatz MIW; Bettoni F; Camargo AA; Asprino PF; A F Galante P
J Pathol; 2022 Feb; 256(2):214-222. PubMed ID: 34816434
[TBL] [Abstract][Full Text] [Related]
5. Molecular comparison of interval and screen-detected breast cancers.
Cheasley D; Li N; Rowley SM; Elder K; Mann GB; Loi S; Savas P; Goode DL; Kader T; Zethoven M; Semple T; Fox SB; Pang JM; Byrne D; Devereux L; Nickson C; Procopio P; Lee G; Hughes S; Saunders H; Fujihara KM; Kuykhoven K; Connaughton J; James PA; Gorringe KL; Campbell IG
J Pathol; 2019 Jun; 248(2):243-252. PubMed ID: 30746706
[TBL] [Abstract][Full Text] [Related]
6. Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA.
Schrader KA; Cheng DT; Joseph V; Prasad M; Walsh M; Zehir A; Ni A; Thomas T; Benayed R; Ashraf A; Lincoln A; Arcila M; Stadler Z; Solit D; Hyman DM; Zhang L; Klimstra D; Ladanyi M; Offit K; Berger M; Robson M
JAMA Oncol; 2016 Jan; 2(1):104-11. PubMed ID: 26556299
[TBL] [Abstract][Full Text] [Related]
7. Genetic predisposition to colorectal cancer: syndromes, genes, classification of genetic variants and implications for precision medicine.
Valle L; Vilar E; Tavtigian SV; Stoffel EM
J Pathol; 2019 Apr; 247(5):574-588. PubMed ID: 30584801
[TBL] [Abstract][Full Text] [Related]
8. Targeting DNA repair: the genome as a potential biomarker.
Nesic K; Wakefield M; Kondrashova O; Scott CL; McNeish IA
J Pathol; 2018 Apr; 244(5):586-597. PubMed ID: 29282716
[TBL] [Abstract][Full Text] [Related]
9. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort.
Waszak SM; Northcott PA; Buchhalter I; Robinson GW; Sutter C; Groebner S; Grund KB; Brugières L; Jones DTW; Pajtler KW; Morrissy AS; Kool M; Sturm D; Chavez L; Ernst A; Brabetz S; Hain M; Zichner T; Segura-Wang M; Weischenfeldt J; Rausch T; Mardin BR; Zhou X; Baciu C; Lawerenz C; Chan JA; Varlet P; Guerrini-Rousseau L; Fults DW; Grajkowska W; Hauser P; Jabado N; Ra YS; Zitterbart K; Shringarpure SS; De La Vega FM; Bustamante CD; Ng HK; Perry A; MacDonald TJ; Hernáiz Driever P; Bendel AE; Bowers DC; McCowage G; Chintagumpala MM; Cohn R; Hassall T; Fleischhack G; Eggen T; Wesenberg F; Feychting M; Lannering B; Schüz J; Johansen C; Andersen TV; Röösli M; Kuehni CE; Grotzer M; Kjaerheim K; Monoranu CM; Archer TC; Duke E; Pomeroy SL; Shelagh R; Frank S; Sumerauer D; Scheurlen W; Ryzhova MV; Milde T; Kratz CP; Samuel D; Zhang J; Solomon DA; Marra M; Eils R; Bartram CR; von Hoff K; Rutkowski S; Ramaswamy V; Gilbertson RJ; Korshunov A; Taylor MD; Lichter P; Malkin D; Gajjar A; Korbel JO; Pfister SM
Lancet Oncol; 2018 Jun; 19(6):785-798. PubMed ID: 29753700
[TBL] [Abstract][Full Text] [Related]
10. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancers.
Jahn A; Rump A; Widmann TJ; Heining C; Horak P; Hutter B; Paramasivam N; Uhrig S; Gieldon L; Drukewitz S; Kübler A; Bermudez M; Hackmann K; Porrmann J; Wagner J; Arlt M; Franke M; Fischer J; Kowalzyk Z; William D; Weth V; Oster S; Fröhlich M; Hüllein J; Valle González C; Kreutzfeldt S; Mock A; Heilig CE; Lipka DB; Möhrmann L; Hanf D; Oleś M; Teleanu V; Allgäuer M; Ruhnke L; Kutz O; Knurr A; Laßmann A; Endris V; Neumann O; Penzel R; Beck K; Richter D; Winter U; Wolf S; Pfütze K; Geörg C; Meißburger B; Buchhalter I; Augustin M; Aulitzky WE; Hohenberger P; Kroiss M; Schirmacher P; Schlenk RF; Keilholz U; Klauschen F; Folprecht G; Bauer S; Siveke JT; Brandts CH; Kindler T; Boerries M; Illert AL; von Bubnoff N; Jost PJ; Metzeler KH; Bitzer M; Schulze-Osthoff K; von Kalle C; Brors B; Stenzinger A; Weichert W; Hübschmann D; Fröhling S; Glimm H; Schröck E; Klink B
Ann Oncol; 2022 Nov; 33(11):1186-1199. PubMed ID: 35988656
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of PALB2-associated breast cancers.
Lee JEA; Li N; Rowley SM; Cheasley D; Zethoven M; McInerny S; Gorringe KL; James PA; Campbell IG
J Pathol; 2018 May; 245(1):53-60. PubMed ID: 29431189
[TBL] [Abstract][Full Text] [Related]
13. Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches.
Roggia C; Armeanu-Ebinger S; Gschwind A; Seibel-Kelemen O; Hertler S; Faust U; Liebmann A; Haack TB; Neumann M; Bonzheim I; Forschner A; Kopp HG; Herster F; Hartkopf A; Bitzer M; Malek NP; Brecht IB; Ruhm K; Möller Y; Löwenheim H; Ossowski S; Rieß OH; Schroeder C
Eur J Cancer; 2023 Jan; 179():48-55. PubMed ID: 36495689
[TBL] [Abstract][Full Text] [Related]
14. [Genomics medicine and oncology].
Michielin O; Coukos G
Praxis (Bern 1994); 2014 May; 103(10):591-6. PubMed ID: 24800772
[TBL] [Abstract][Full Text] [Related]
15. Cancer Predisposition Sequencing Reporter (CPSR): A flexible variant report engine for high-throughput germline screening in cancer.
Nakken S; Saveliev V; Hofmann O; Møller P; Myklebost O; Hovig E
Int J Cancer; 2021 Dec; 149(11):1955-1960. PubMed ID: 34310709
[TBL] [Abstract][Full Text] [Related]
16. Substantial batch effects in TCGA exome sequences undermine pan-cancer analysis of germline variants.
Rasnic R; Brandes N; Zuk O; Linial M
BMC Cancer; 2019 Aug; 19(1):783. PubMed ID: 31391007
[TBL] [Abstract][Full Text] [Related]
17. NTHL1 and MUTYH polyposis syndromes: two sides of the same coin?
Weren RD; Ligtenberg MJ; Geurts van Kessel A; De Voer RM; Hoogerbrugge N; Kuiper RP
J Pathol; 2018 Feb; 244(2):135-142. PubMed ID: 29105096
[TBL] [Abstract][Full Text] [Related]
18. Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
Mandelker D; Zhang L; Kemel Y; Stadler ZK; Joseph V; Zehir A; Pradhan N; Arnold A; Walsh MF; Li Y; Balakrishnan AR; Syed A; Prasad M; Nafa K; Carlo MI; Cadoo KA; Sheehan M; Fleischut MH; Salo-Mullen E; Trottier M; Lipkin SM; Lincoln A; Mukherjee S; Ravichandran V; Cambria R; Galle J; Abida W; Arcila ME; Benayed R; Shah R; Yu K; Bajorin DF; Coleman JA; Leach SD; Lowery MA; Garcia-Aguilar J; Kantoff PW; Sawyers CL; Dickler MN; Saltz L; Motzer RJ; O'Reilly EM; Scher HI; Baselga J; Klimstra DS; Solit DB; Hyman DM; Berger MF; Ladanyi M; Robson ME; Offit K
JAMA; 2017 Sep; 318(9):825-835. PubMed ID: 28873162
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic and molecular dissection of metaplastic breast cancer and the prognostic implications.
McCart Reed AE; Kalaw E; Nones K; Bettington M; Lim M; Bennett J; Johnstone K; Kutasovic JR; Saunus JM; Kazakoff S; Xu Q; Wood S; Holmes O; Leonard C; Reid LE; Black D; Niland C; Ferguson K; Gresshoff I; Raghavendra A; Harvey K; Cooper C; Liu C; Kalinowski L; Reid AS; Davidson M; Pearson JV; Pathmanathan N; Tse G; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox SB; O'Toole SA; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2019 Feb; 247(2):214-227. PubMed ID: 30350370
[TBL] [Abstract][Full Text] [Related]
20. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
